Post Date: June 25, 2020 | Publish Date: June 25, 2020
“The study shows clearly that the optimized dosing strategy for hydroxyurea, though it requires more effort than a fixed-dose treatment regimen, results in far better outcomes for children with sickle cell anemia,”
— Russell Ware, MD, PhD
|Original Title:||Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa|
|Published in:||New England Journal of Medicine|
|Publish date:||June 25, 2020|
The Research Horizons blog features news and insights about the latest discoveries and innovations developed by the scientists of Cincinnati Children's. This blog does not provide medical advice, diagnosis, or treatment.